What is BML, Inc.?
provides contract clinical testing and related services in Japan.
BMLKF · Verdict
Limited reward · moderate risk
BMLKF's standout is volatility; profitability and growth weigh on the picture.
Based on 88% data coverage
BMLKF · Verdict
Top decile vs peers
4% net margin · 6% ROE
Rev -8.4% CAGR · earnings -43.0%
Model-based scoring. For information only — not financial advice.
provides contract clinical testing and related services in Japan. The company offers a range of laboratory testing, such as biochemical and hematologic examination; laboratory test, including tumor markers, infectious diseases, hormones, cellular immunity, genetics, bacteriological tests, and other test; specialized testing in oncology, infectious diseases, diabetes, hypertension, allergies, genetics, and more areas, as well as develops Frontier and Symphony automation systems, which automate pre-testing from specimen sorting to dispensing. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 944.85M, and a P/E ratio of 22.1x.
The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are moderate, consistent with typical market exposure.
For informational purposes only. Not financial advice.